Derniers essais

EudraCT Number: 2018-000537-12

Sponsor Protocol Number: 35RC17_EsPhALL2017-02

Start Date:

Sponsor Name: CHU de Rennes

Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Medical condition: Philadelphia chromosome-positive acute lymphoblastic leukemia

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10000845	Acute lymphoblastic leukemia	LLT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2005-005563-28

Sponsor Protocol Number: EMR 64300-607

Start Date:

Sponsor Name: University Clinic Essen

Full Title: PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan

Medical condition: Patients at high risk for CVD

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2020-000917-34

Sponsor Protocol Number: 20-214-29/CA045-022

Start Date:

Sponsor Name: Nektar Therapeutics

Full Title: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk...

Medical condition: Resected Stage IIIA (lymph node metastasis > 1 mm)/B/C/D and IV melanoma with no evidence of disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025650	Malignant melanoma	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) FR (Completed) GR (Completed) PL (Completed) AT (Completed) PT (Prematurely Ended) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) RO (Prematurely Ended)

Trial results: View results

EudraCT Number: 2018-002876-41

Sponsor Protocol Number: 38RC18.123

Start Date:

Sponsor Name: CHU Grenoble-Alpes

Full Title: Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration)

Medical condition: Respiratory Distress Syndrome of preterm babies born

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Preterm newborn infants, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-004004-30

Sponsor Protocol Number: 111-205

Start Date:

Sponsor Name: BioMarin Pharmaceutical Inc.

Full Title: A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia

Medical condition: achondroplasia

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10000452	Achondroplasia	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2006-005346-37

Sponsor Protocol Number: F1D-MC-HGMR

Start Date:

Sponsor Name: Eli Lilly and Company Limited

Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ...

Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10061345	Pervasive developmental disorder	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-017803-27

Sponsor Protocol Number: MYOCET

Start Date:

Sponsor Name: CHU DE NANCY

Full Title: ESSAI DE PHASE I DE MYOCET® CHEZ DES ENFANTS AYANT UN GLIOME MALIN REFRACTAIRE OU EN RECHUTE

Medical condition: Enfants ayant un gliome malin réfractaire ou en rechute.

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-001453-31

Sponsor Protocol Number: CONMED3

Start Date:

Sponsor Name: Copenhagen University Hospital Rigshospitalet

Full Title: Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study

Medical condition: We investigate the possible effects of commercially available apomorphine and methylphenidate on signatures of consciousness in patients admitted to the ICU with acute disorder of consciousness, us...

Disease:	Version	SOC Term	Classification Code	Term	Level
	25.1	10029205 - Nervous system disorders	10013509	Disturbances in consciousness NEC	HLT
	21.1	10029205 - Nervous system disorders	10067967	Brain injury	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: (No results available)

EudraCT Number: 2007-006044-22

Sponsor Protocol Number: HGT-ELA-038

Start Date:

Sponsor Name: Shire Human Genetic Therapies, Inc. (Shire HGT)

Full Title: A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy

Medical condition: Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome)

Disease:	Version	SOC Term	Classification Code	Term	Level
	10.1		10056889		PT

Population Age: Newborns, Infants and toddlers, Children, Under 18

Gender: Male

Trial protocol: PL (Completed)

Trial results: View results

EudraCT Number: 2007-005786-35

Sponsor Protocol Number: DC02RUP/IV/02

Start Date:

Sponsor Name: Uriach Pharma

Full Title: Proof-of-concept, cross over, double blind, placebo-controlled study to assess if Rupatadine 20 mg can improve critical stimulation time thresholds (CSTTs) in patients with acquired cold urticaria

Medical condition: Acquired Cold Urticaria

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10009869	Cold urticaria	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Ongoing)

Trial results: (No results available)

Derniers essais

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue